Lifecore Biomedical Q3 Misses Street Estimates, Explores 'Strategic Alternatives'

Zinger Key Points
  • The company is currently evaluating "strategic alternatives" to boost stockholder value.
  • Curation Foods segment revenues declined 51% Y/Y to $1.27 million.

Lifecore Biomedical Inc LFCR reported a Q3 FY23 revenue decline of 26% Y/Y to $27.60 million, missing the consensus of $28 million

  • Segment revenues fell 24% Y/Y to $26.3 million due to a decline in its CDMO business and Hyaluronic Acid raw material manufacturing (fermentation) business. 
  • Curation Foods segment revenues also declined 51% Y/Y to $1.27 million.
  • Gross profit was down 53.5% Y/Y to $6 million. 
  • Adjusted EBITDA declined 78% Y/Y to $1.45 million.
  • Adjusted EPS loss of $0.22, vs $0.06 a year ago, worse than the consensus loss of $0.13
  • Cash used in operations stood at $17.2 million vs $22 million a year ago.
  • Cash and cash equivalents of $3 million at the end of the quarter.
  • Lifecore recently executed an enhanced Supply Agreement with a significant, long-term customer, Alcon, as well as completing a comprehensive restructuring of its debt arrangements.
  • These transactions allow Lifecore to clear the existing Going Concern qualification and create a more stable and sustainable business model.
  • "In combination with the sale of our remaining Curation Foods segment business in early April, Lifecore is beginning a new chapter as a stand-alone CDMO," CEO James Hall says.
  • The company is currently evaluating "strategic alternatives" to maximize stockholder value, he added.

Price Action: LFCR shares are trading lower by 2.32% at $8.00 premarket on the last check Thursday.

 

 

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesM&ANewsHealth CareSmall CapTop StoriesMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!